Abstract
We conducted a phase II study to evaluate the efficacy and safety of chemoradiotherapy concurrent with S-1 plus cisplatin in patients with unresectable locally advanced squamous cell carcinoma of the head and neck. Chemotherapy consisted of S-1 twice daily on days 1-14 at 60 mg/m(2) /day and cisplatin at 20 mg/m(2) /day on days 8-11, repeated twice at a 5-week interval. Single daily radiation of 70 Gy in 35 fractions was given concurrently starting on day 1. For patients achieving an objective response after chemoradiotherapy, two additional cycles of chemotherapy were administered. Of the 45 enrolled patients, the percentage of clinical complete remission, the primary endpoint, was 64.4% (8 complete response, 21 good partial response) on central review. After a median follow-up of 3.52 years, 3-year local progression-free survival was 62.2%, with 3-year progression-free survival of 60.0%, 3-year overall survival of 64.4%, and 3-year time to treatment failure of 48.9%. Grade 3 or 4 toxicity included pharyngeal mucositis (46.7%), oral mucositis (44.4%), dysphagia (46.7%), anorexia (42.2%), radiation dermatitis (26.7%), neutropenia (26.7%), and febrile neutropenia (4.4%). No treatment-related deaths were observed. This combinatio...Continue Reading
References
May 1, 1992·Statistics in Medicine·S J Green, S Dahlberg
Jan 1, 1992·International Journal of Radiation Oncology, Biology, Physics·G E LaramoreJ G Schwade
Mar 13, 1999·International Journal of Cancer. Journal International Du Cancer·D M ParkinJ Ferlay
Dec 10, 1999·Annals of Clinical Biochemistry·J van der Weide, L S Steijns
Jun 16, 2001·Head & Neck·G P BrowmanUNKNOWN Cancer Care Ontario Practice Guideline Initiative Head and Neck Cancer Disease Site Group
Jun 4, 2002·Pharmacogenetics·Satoshi DaigoTetsuya Kamataki
Sep 8, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jaffer A AjaniPeter Urrea
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
May 19, 2009·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Jean-Pierre PignonUNKNOWN MACH-NC Collaborative Group
Feb 18, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jaffer A AjaniSilvia Falcon
Jun 10, 2010·The New England Journal of Medicine·K Kian AngMaura L Gillison
Aug 11, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Danny RischinGrant A McArthur
Sep 30, 2010·Oncology Reports·Masakazu FukushimaYu Sakata
Dec 8, 2010·Cancer Science·Makoto TaharaAtsushi Ohtsu
Jan 15, 2011·The Lancet Oncology·Jochen H LorchUNKNOWN TAX 324 Study Group
Feb 15, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M R PosnerK J Cullen
Oct 5, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anil K ChaturvediMaura L Gillison
Sep 1, 2012·International Journal of Clinical Oncology·Takatsugu MizumachiSatoshi Fukuda
Citations
Oct 27, 2018·Japanese Journal of Clinical Oncology·Takashi MatsuzukaUNKNOWN Japan Clinical Oncology Group(JCOG) Head and Neck Cancer Study Group
Jan 19, 2019·International Journal of Clinical Oncology·Satoshi HamauchiAkihiro Homma
Oct 31, 2019·Japanese Journal of Clinical Oncology·Yoshinori ImamuraUNKNOWN Japan Clinical Oncology Group (JCOG) Head and Neck Cancer Study Group
Jan 17, 2020·Cancer Medicine·Tomohiro EnokidaMakoto Tahara
Feb 22, 2018·Oncotarget·Yasumasa EzoeManabu Muto
Feb 6, 2017·Japanese Journal of Clinical Oncology·Tomoko YamazakiKunihiro Yoshisue
Dec 19, 2018·Medicine·Shuai QieXi Zhang
Oct 1, 2020·International Journal of Clinical Oncology·Jun TaguchiHirotoshi Dosaka-Akita
Aug 25, 2016·Cancer Control : Journal of the Moffitt Cancer Center·Taro MuraiYuta Shibamoto
Apr 17, 2021·Journal of Oncology·Ximing ZhangZiyang Chen
Jun 25, 2021·International Journal of Clinical Oncology·Makoto TaharaRyuichi Hayashi